Renovacor (Renovacor) ROE % Adjusted to Book Value : -122.97% (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Renovacor ROE % Adjusted to Book Value?

Renovacor's ROE % for the quarter that ended in Sep. 2022 was -121.74%. Renovacor's PB Ratio for the quarter that ended in Sep. 2022 was 0.99. Renovacor's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 was -122.97%.

Renovacor ROE % Adjusted to Book Value Historical Data

The historical data trend for Renovacor's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor ROE % Adjusted to Book Value Chart

Renovacor Annual Data

Trend

Dec20

Dec21

ROE % Adjusted to Book Value

-19.89

Renovacor Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROE % Adjusted to Book Value	Get a 7-Day Free Trial				-20.95	-1.65	39.45	-46.20	-122.97

Competitive Comparison of Renovacor's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Renovacor's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovacor's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Renovacor's ROE % Adjusted to Book Value falls into.

Renovacor ROE % Adjusted to Book Value Calculation

Renovacor's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2021 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-47.93%	/	2.41
	=	-19.89%

Renovacor's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-121.74%	/	0.99
	=	-122.97%

Renovacor ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Renovacor's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 8142, Greenwich, CT, USA, 06836

Website

https://www.renovacor.com

Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Executives

Joseph S Carroll	officer: Chief Accounting Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino	director	C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr.	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll	officer: Chief Financial Officer
Jonas Grossman	director	17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook	director, officer: Chief Executive Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen	officer: Chief Scientific Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran	officer: Chief Medical Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco	officer: Interim CFO